Glenmark's favipiravir version shows promise in late-stage Covid-19 trial

Representative image. Credits: Reuters Photo

India's Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.

For latest updates on Coronavirus outbreak, click here

About 70% of patients being treated by FabiFlu achieved "clinical cure" by the fourth day of the study, compared with about 45% seen in the group treated with standard supportive care, the company said in a statement